FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Slideshows|October 1, 2018
HCV in Young Adults and Children: 3 Studies At-a-Glance
Author(s)Andrew D. Bowser
Study summaries highlight increased infection rates in young adults; a spike in HCV in reproductive-aged women; and a potential new treatment for HCV in young children.
Advertisement
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5